Mfg Part Number
Ab02055-23.0
Vector Labs Ab02055-23.0 Anti-TCR [BMA031], Rabbit IgG, kappa (200 μg)
Quick Overview
The original antibody was generated by immunizing mice with human perihperal blood T-lymphocytes.
$517.40
Order will ship within 1-3 business days
| Product Class: | Purified |
|---|---|
| Clone ID: | BMA031 |
| Synonyms: | Human α/β T Cell Receptor (TCR) |
| Amount: | 200 μg |
| Application Codes Clone: | IF; IP; FACS; Block |
| Shipping Temperature: | Wet Ice |
| Buffer Composition: | PBS with 0.02% Proclin 300. |
| Original Format: | IgG2b |
| Storage Temperature: | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C. |
| Chimeric Use Statement: | This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2b format, for improved compatibility with existing reagents, assays and techniques. |
| Specificity Statement: | This antibody reacts with surface receptors on all alpha-beta TCR bearing cells, but does not react with receptors on gamma-delta T cells. TCR-αβ is expressed by the majority of mature CD3+ T cells. |
| Application Notes: | This antibody is recomended for detection of viable human αβ+ TCR lymphocyte. It is highly effective in modulating immune reactions and is capable of activating human T lymphocytes in vito (PMID: 3092794). Double immunofluorescence staining was used to ascertain that this antibody does not cross react with γδ+ TCR cells. FACS analysis confirmed that BMA031 did not react with γδ+ TCR cells. BMA031 successfully precipitates TCR αβ/CDR complex (PMID: 1704361). BMA031 in conjugation with triple drug induction treatment in kidney-transplanted patients showed no side effects and reduction in graft rejections (PMID: 2978369). A clinical phase II trial administered 50 mg of murine anti-human alpha/beta-TCR mAb (BMA 031) intravenously on the day of, as well as 2 and 4 days after, cadaveric donor renal transplantation in combination with a CsA/prednisone regimen. After a minimum of 30 months follow-up, the actual allograft survival rate was 87% in the BMA-treated group compared with 68% in the control cohort (PMID: 8009591).Humanized version of this antibody BMA 031-EUCIV3 is found to have 2.5 times less affinity than its murine parent, however the ability to cause antibody dependent cell-mediated cytolysis was significantly enhanced (PMID: 1836485). |
| Brand | Vector Labs |
|---|---|
| UNSPSC | 12161500 |